For the rat studies cited (but not detailed in this paper), the effects of myristicin on liver enzymes and DNA adduct formation were investigated in rodents. The specific protocols (dose, route, duration) are not described in this paper. [2]

Metabolism / Metabolites
In mice, the main metabolic pathway of Myristicin involves the cleavage of methylenedioxyphenol residues and the excretion of the methylene carbon atom as carbon dioxide. Myristicin may generate 3-methoxycatechol in mice and houseflies; 1-(3-methoxy-4,5-methylenedioxyphenyl)-3-piperidinyl-1-propanone in rats and guinea pigs; and 1-(3-methoxy-4,5-methylenedioxyphenyl)-3-pyrrolidinyl-1-propanone in rats and guinea pigs. /Excerpt from table/ During perfusion of isolated rat liver or incubation with rat liver homogenate, Myristicin is converted to 3-methoxy-4,5-methylenedioxyphenylamine. Following oral or intraperitoneal injection, two nitrogenous Myristicin metabolites are excreted in the urine of rats and guinea pigs. In rats, the metabolite is 3-piperidinyl-1,3-methoxy-4,5-methylenedioxyphenyl)-1-propanone, while in guinea pigs, the major metabolite is 3-pyrrolidinyl-1-(3-methoxy-4,5-methylenedioxyphenyl)-1-propanone. For more complete data on the metabolism/metabolites of Myristicin (a total of 8 metabolites), please visit the HSDB record page. Known human metabolites of Myristicin include 5-allyl-1-methoxy-2,3-dihydroxybenzene.

Toxicity Summary
Myristone may have neurotoxic effects on dopaminergic neurons and is a weak inhibitor of monoamine oxidase. (L1271) Toxicity Data
LD50: 3000 mg/kg (oral, mouse) (L1272) LD50: 340 mg/kg (intraperitoneal, mouse) (L1272) LD50: 5610 mg/kg (dermal, rat) (L1272) LD50: 1470 mg/kg (subcutaneous, mouse) (L1272) LD50: 8000 mg/kg (intramuscular, mouse) (L1272) Interactions Concurrent topical application of myristone and paraoxon significantly increases the toxicity of paraoxon. The LD50 value indicates that topical application of myristyl ether within the sublethal dose range of 2 micrograms per fly can increase the toxicity of paraoxon by 10 times.

[1]. Nutmeg as a narcotic. A contribution to the chemistry and pharmacology of nutmeg (Myristica fragrans).Angew Chem Int Ed Engl. 1971 Jun;10(6):370-4.

[2]. Simple and rapid determination of myristicin in human serum.Forensic Toxicol. 2013 Jan;31(1):119-123. Epub 2012 Aug 15.

[3]. Protective effects of myristicin against ulcerative colitis induced by acetic acid in male mice. Food and Agricultural Immunology, 2020, 31(1): 435-446.

[4]. Myristicin Suppresses Gastric Cancer Growth via Targeting the EGFR/ ERK Signaling Pathway. Curr Mol Pharmacol. 2023;16(7):712-724.

Myristicin is an organic molecule and a metabolite. It has been reported to be present in perilla, asarum, and several other organisms with relevant data. Fennel also contains Myristicin. Myristicin is a component of dill, nutmeg, parsley, and many other essential oils. High doses of nutmeg may produce psychoactive effects. Myristicin, 3-methoxy-4,5-methylenedioxyallylbenzene, is a natural organic compound found in nutmeg essential oil and in smaller amounts in other spices such as parsley and dill. Myristicin is a naturally occurring insecticide and acaricide and may have neurotoxic effects on dopaminergic neurons [citation needed]. Its hallucinogenic doses are far higher than those used in cooking. Myristicin is a weak monoamine oxidase inhibitor. Studies have shown that Myristicin has pro-apoptotic and hepatoprotective effects (A7836, A7837).
Myristicin belongs to the benzodioxane class of compounds. These organic compounds contain a benzene ring fused with an isomer of dioxane.

---

Mechanism of Action
To evaluate the hepatoprotective activity of spices, we fed rats with liver injury induced by lipopolysaccharide (LPS) and D-galactosamine (D-GalN) with 21 different spices. Nutmeg exhibited the strongest hepatoprotective activity as assessed by plasma aminotransferase activity. We isolated the active compounds in nutmeg under bioactivity-directed administration to mice via single oral administration of the corresponding extracts. Myristicin is one of the main essential oils of nutmeg and has been found to possess extremely strong hepatoprotective activity. Myristicin significantly inhibited LPS/D-galactosamine-induced increases in serum TNF-α concentration and liver DNA fragmentation in mice. These results suggest that the hepatoprotective activity of Myristicin may be at least partially attributed to its inhibitory effect on macrophage release of TNF-α. …
To evaluate the role of Myristicin in Cyp1a-1 induction, we treated mouse hepatocellular carcinoma cells Hepa-1c1c7 (Hepa-1) with Myristicin. The results showed that Myristicin treatment of Hepa-1 cells increased Cyp1a-1 transcription levels in a dose-dependent manner, which was confirmed by analysis of 7-ethoxyhalothrin O-deethylase activity, Cyp1a-1 protein levels, and Cyp1a-1 mRNA levels. However, in competitive aryl hydrocarbon receptor binding assays using sucrose density gradient sedimentation, Myristicin did not competitively substitute for [3H]2,3,7,8-tetrachlorodibenzo-p-dioxin on the Hepa-1 cytoplasmic aryl hydrocarbon (Ah) receptor; and in gel migration variation assays using oligonucleotides corresponding to Cyp1a-1 DRE 3, Myristicin did not affect the formation of the DNA-protein complex between the Ah receptor and its DRE target.

C11H12O3

192.21

192.078

607-91-0

4276

Colorless to light yellow liquid

1.1±0.1 g/cm3

276.5±0.0 °C at 760 mmHg

<-20ºC

89.8±16.0 °C

0.0±0.5 mmHg at 25°C

1.540

3.26

0

3

3

14

205

0

C=CCC1=CC(=C2C(=C1)OCO2)OC

BNWJOHGLIBDBOB-UHFFFAOYSA-N

InChI=1S/C11H12O3/c1-3-4-8-5-9(12-2)11-10(6-8)13-7-14-11/h3,5-6H,1,4,7H2,2H3

4-methoxy-6-prop-2-enyl-1,3-benzodioxole

HSDB 3516 HSDB3516Myristicin HSDB-3516

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture.

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ~100 mg/mL (~520.26 mM)

Solubility in Formulation 1: ≥ 2.5 mg/mL (13.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.5 mg/mL (13.01 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

View More

Solubility in Formulation 3: ≥ 2.5 mg/mL (13.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

 (Please use freshly prepared in vivo formulations for optimal results.)